Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo. [PDF]
PLoS ONE, 2013 VEGF family factors are known to be the principal stimulators of abnormal angiogenesis, which play a fundamental role in tumor and various ocular diseases. Inhibition of VEGF is widely applied in antiangiogenic therapy.
Qin Wang +6 more
doaj +1 more source
Conbercept Versus Conbercept Combined with Retinal Photocoagulation for Macular Edema Secondary to Branch Retinal Vein Occlusion [PDF]
, 2021 Abstract Background: To evaluate the efficacy of intravitreal injection of conbercept (IVC) with or without laser photocoagulation for recurrent macular edema secondary to branch retinal vein occlusion (BRVO). Methods: 82 patients (82 eyes) with recurrent macular edema secondary to BRVO were collected.
Gengmin Tong +3 more
openaire +1 more source
Intravitreal Therapy for Diabetic Macular Edema: An Update [PDF]
, 2021 Diabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite that DME represents a sight-Threatening condition, it is also among the most accessible to treatment.
Alessio G. +3 more
core +1 more source
Systematic Reviews, 2021 Background The comparative safety and efficacy between anti-vascular endothelial growth factor agents (anti-VEGFs) and between combined therapies for patients with neovascular age-related macular degeneration (nAMD) is unclear.
Andrea C. Tricco +17 more
doaj +1 more source
Effect of subconjunctival injection with conbercept as an adjuvant to filtration surgery for open angle glaucoma: a prospective randomized interventional 6-month follow-up study [PDF]
International Journal of Ophthalmology, 2019 AIM: To compare the safety and efficacy of subconjunctival injection with conbercept and 5-fluorouracil (5-FU) for open angle glaucoma (OAG) patients after filtration surgery.
Jing Zhang +6 more
doaj +1 more source
Frontiers in Medicine, 2022 PurposeTo investigate the intravitreal injection of conbercept as a treatment strategy for proliferative diabetic retinopathy (PDR) with or without center-involved diabetic macular edema (CI-DME) and evaluate its effect on the microvascular changes in ...
Wei Lin +25 more
doaj +1 more source
Anti-VEGF therapy and retinopathy of prematurity [PDF]
, 2023 Introduction:Nowadays, anti-vascular endothelial growth factor (VEGF) therapy is widely used as first-line therapy for retinopathy of prematurity (ROP) with very good therapeutic and visual results.Aim:The aim of the present study is to compare the ...
Manolova, Yana, Shangova, Kaloyana
core +2 more sources
Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy [PDF]
, 2023 BackgroundProliferative diabetic retinopathy (PDR) is an advanced complication of diabetic retinopathy that can cause blindness. It consists of thepresence of new vessels in the retina and vitreous haemorrhage.
Cordero Rigol, José Antonio +8 more
core +1 more source
Frontiers in Medicine, 2021 Background: With the advent of aging society of China, fundus diseases related to pathological neovascularization, including age-related macular degeneration (AMD), diabetic macular edema (DME), and pathological myopia (PM), have become an increasingly ...
Zhuang Cui +7 more
doaj +1 more source
Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling. [PDF]
PLoS ONE, 2013 Conbercept is a genetically engineered homodimeric protein for the treatment of wet age-related macular degeneration (wet AMD) that functions by blocking VEGF-family proteins.
Zhigang Wu +7 more
doaj +1 more source